Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors
Thomas J. Semrad(University of California, Davis), Karen Kelly(Cancer Research Center), Mili Arora(UC Davis Comprehensive Cancer Center), Tianhong Li(VA Northern California Health Care System), Jonathan W. Riess(University of California Davis Medical Center), Edward Kim(University of California, Davis), Scott Christensen(UC Davis Comprehensive Cancer Center), I-Yeh Gong(Kaiser Permanente), David R. Gandara(University of California, Davis)
Cited by 12
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k